BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Chendu DIAO Pharmaceutical Group readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Chendu DIAO Pharmaceutical Group'
 s drugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07629544-225@assetmemo.bio
DTSTAMP:20261121T005929Z
DTSTART;VALUE=DATE:20270709
DTEND;VALUE=DATE:20270710
SUMMARY:DA-302168S: Phase 3 readout est. (NCT07629544)
DESCRIPTION:DA-302168S\, phase 3\, Obesity.\nStudy: A Study of DA-302168S i
 n Participants With Overweight/Obesity\nEstimated primary completion: 9 Ju
 ly 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/da-302168s#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07629
 544
URL:https://assetmemo.bio/drug/da-302168s#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07755150-225@assetmemo.bio
DTSTAMP:20261121T005929Z
DTSTART;VALUE=DATE:20271020
DTEND;VALUE=DATE:20271021
SUMMARY:DA-302168S: Phase 2 readout est. (NCT07755150)
DESCRIPTION:DA-302168S\, phase 2\, Type 2 Diabetes.\nStudy: A Study to Eval
 uate the Efficacy and Safety of DA-302168S Tablets in Subjects With Type 2
  Diabetes\nEstimated primary completion: 20 October 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/da-302168s#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07755150
URL:https://assetmemo.bio/drug/da-302168s#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
